Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
34 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
- D3.24 - From angioedema to Kimura disease: Diagnostic challenge
- D3.27 - Chlorhexidine as a Hidden Everyday Allergen
D3.17 - Systemic Histaminergic Findings in Children with Chronic Urticaria
D3.18 - Allergy to Isobornyl Acrylate (IBOA) present in Sensors and Insulin Infusion Systems in Pediatric Population
D3.19 - Evaluation of allergens in Atopic Dermatitis in children between 6 months and 18years
D3.20 - Searching for an Alternative Contrast Agent in a Patient Allergic to Multiple Nonionic Iodinated Contrast Media
D3.22 - Fixed Drug Eruption in a Patient with Vitiligo: localized patch testing as a diagnostic tool
D3.23 - Descriptive and Comparative Analysis of Clinical and Endoscopic Characteristics and Treatment Response in Adult Patients with Eosinophilic Esophagitis (EoE): a preliminary experience of an Italian centre
D3.26 - Anaphylaxis associated with biosimilar Tocilizumab: in vitro and in vivo diagnosis
D3.28 - Comparative Efficacy and Safety of Omalizumab Intended copy Biosimilar vs. Biologic in Chronic Spontaneous Urticaria
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download